... and instead both Bloomberg and StatNews report that Trump will announce that a new coronavirus treatment involving blood plasma from patients who have recovered from the disease, has received an emergency use authorization from the FDA, which is expected to clear for use with certain patients what's known as convalescent plasma. The move, Bloomberg notes,  would make it easier for patients to get the product, which Trump has touted even though its effectiveness hasn't been proved.

Blood plasma is among a host of potential therapeutics that have been undergoing testing in clinical trials, StatNews notes adding that the hope is that infusions of antibody-rich plasma from those who have recovered from Covid-19 can be injected into ill patients, kickstarting their immune system and allowing them to fight off the virus until they can generate their own antibodies.

Trump's decision to forge ahead is predicated by a study conducted by the Mayo Clinic and the National Institutes of Health which found that plasma treatments appeared to have a small but statistically significant impact on reducing mortality in hospitalized Covid-19 patients who received the infusions within three days of the onset of symptoms, compared with those who got plasma later.